Main Reference
Infectious Disease

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Cancer Internal Medicine Infectious Disease Viral Infectious Diseases Adult Subjects Female Subjects Male Subjects

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

HPV Functional CT Assessment

Radiology Pulmonology Infectious Disease Heart and Vascular Airway Disease Viral Infectious Diseases Lung Disease Vascular Disease Healthy Subjects Adult Subjects Female Subjects Male Subjects

This study will use dual energy x-ray computed tomography (DECT) to evaluate the relationship between heterogeneous perfusion, hypoxia (low oxygen in inspired gas) and induction of pulmonary vascular dilatation to characterize emphysema susceptibility in a normal smoking population. The investigators will correlate DECT measures of perfusion with lung injury measured by single photon emission computed tomography (SPECT). The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema

Subscribe to Viral Infectious Diseases